The Correlation of Inflammatory Markers with Clinical Manifestation, Peritumoral Edema, and Recurrence in Meningioma Patients
Abstract
Background: Meningiomas can induce inflammation in their tumorigenesis process, thereby linking inflammation with clinical symptoms, peritumoral edema, and recurrence of meningiomas. Easily accessible and cost-effective inflammatory markers include the neutrophillymphocyte ratio (NLR) and monocyte-lymphocyte ratio (MLR). This study aims to investigate the relationship between peripheral inflammation markers, specifically the NLR and MLR, and their association with clinical symptoms, peritumoral edema, and meningioma recurrence.
Method: A retrospective cohort study was conducted at Cipto Mangunkusumo National General Hospital from January 2016 to December 2019, utilizing a consecutive non-probability sampling method. Inclusion criteria were patients aged 18 years or older with meningiomas(gradesI-III), first surgery. Peripheral inflammatory markers were derived from differential blood counts, peritumoral edema data from radiological reports, and other data from medical records. The cut-off valuesfor NLR and MLR were determined to be 2.415 and 0.295, respectively. Bivariate analyses using ChiSquare and Mann-Whitney tests were followed by multivariate logistic regression analysis.
Results: 173 patients were eligible for analysis. Of these, 27 had preoperative CT scans, 126 had MRIs, and 20 had no preoperative radiology data. Clinical and recurrence analyses were performed on all 173 patients, with radiology and tumor size analyses conducted on subsets of 153 and 126 patients, respectively. The majority of meningiomasin thisstudy were grade I, found in 94.2% of subjects, with the remainder being grade II and III. Higher NLR and MLR values were significantly associated with headaches (p < 0.001). Elevated NLR and MLR were also correlated with peritumoral edema (p < 0.001). MLR was independently associated with recurrence, with an adjusted odds ratio (aOR) of 12.647 (95% CI 2.355–67.919); p = 0.003.
Conclusion: NLR and MLR as peripheral inflammatory markers demonstrated higher median values in meningioma patients with headaches and peritumoral edema. Additionally, inflammation in meningiomas was associated with the occurrence of recurrence.
Keywords
DOI: 10.33371/ijoc.v19i2.1287
Article Metrics
Abstract View: 478, 
PDF Download: 124
References
Malueka RG. Tinjauan umum tumor sistem saraf pusat. Dalam: Aninditha T, Andriani R, Malueka RG, editors. Buku Ajar Neuroonkologi. 1st ed. Jakarta: Penerbit Kedokteran Indonesia; 2019. Hal. 13–19.
Hortobágyi T, Bencze J, Varkoly G, et al. Meningioma recurrence. Open Medicine (Poland). 2016;11(1):168–73.
Buerki RA, Horbinski CM, Kruser T, et al. An overview of meningiomas. Future Oncol. 2018;14(21):2161–77.
Aninditha T. Meningioma dan tumor meningeal lainnya. Dalam: Aninditha T, Andriani R, Malueka RG, editors. Buku Ajar Neuroonkologi. Jakarta: Penerbit Kedokteran Indonesia; 2019. p. 115–26.
Hanahan D, Weinberg RA. Hallmark of cancer: an organizing principle for cancer medicine. in: Devita VT, Lawrence TS, Rosenberg SA, editors. Cancer Principles & Practice of Oncology. 11th ed. Philadelphia: Wolters Kluwer; 2019.
Garzon-Muvdi T, Bailey DD, Pernik MN, et al. Basis for Immunotherapy for Treatment of Meningiomas. Front Neurol. 2020;11(August):1–11.
Bunevicius A, Radziunas A, Tamasauskas S, et al. Prognostic role of high sensitivity c-reactive protein and interleukin-6 in glioma and meningioma patients. J Neurooncol. 2018;138(2):351
Kuranari Y, Tamura R, Tsuda N, et al. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in patients with meningiomas. Front Oncol. 2020 Nov 24;10.
Qin L. The predictive value of NLR, PLR and MLR in the differential diagnosis of benign uterine diseases and endometrial malignant tumors. Discov Oncol. 2024 Mar 31;15(1):91.
Baratawidjaja KG, Rengganis I. Imunologi Dasar. XII. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2018. 53–76.
Guenther F, Swozil F, Heber S, et al. Pre and post operative headache in patients with meningioma. Cephalalgia. 2019;39(4):533–43.
St-Onge M, Flamand N, Biarc J, et al. Characterization of prostaglandin E2 generation through the cyclooxygenase (COX)-2 pathway in human neutrophils. Biochem Biophys Acta. 2007 Sep;1771(9):1235–45.
Lieu AS, Howng SL. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res. 2000 Jan;38(1):45-52.
Simis A, Pires de Aguiar PH, Leite CC, et al. Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol. 2008;70(5):471–7.
Morsy M, El-Saadany W, Moussa W, et al. Predictive factors for seizures accompanying intracranial meningiomas. Asian J Neurosurg. 2019;14(2):403.
Fares J, Fares MY, Fares Y. Natural killer cells in the brain tumor microenvironment: defining a new era in neuro-oncology. Surg Neurol Int. 2019;10(43):1–4.
Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12(1):1–16.
Berhouma M, Jacquesson T, Jouanneau E, et al. Pathogenesis of peri-tumoral edema in intracranial meningiomas. Neurosurg Rev. 2019;42(1):59–71.
Kemerdere R, Akgun MY, Toklu S, et al. Preoperative systemic inflammatory markers in low- and high-grade gliomas: A retrospective analysis of 171 patients. Heliyon. 2019;5(5):e01681.
Kim BW, Kim MS, Kim SW, et al. Peritumoral brain edema in meningiomas: Correlation of radiologic and pathologic features. J Korean Neurosurg Soc. 2011;49(1):26–30.
Ressel A, Fichte S, Brodhun M, et al. WHO grade of intracranial meningiomas differs with respect to patient’s age, location, tumor size and peritumoral edema. J Neurooncol. 2019 Nov 1;145(2):277–86.
Proctor DT, Huang J, Lama S, et al. Tumor-associated macrophage infiltration in meningioma. Neurooncol Advances. 2019 May 1;1(1).
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
